KB Financial Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-9,691
Closed -$739K 642
2023
Q1
$739K Buy
9,691
+101
+1% +$8.38K 0.22% 49
2022
Q4
$796K Buy
9,590
+65
+0.7% +$5.26K 0.27% 45
2022
Q3
$756K Buy
9,525
+1,275
+15% +$107K 0.27% 39
2022
Q2
$613K Buy
+8,250
New +$619K 0.21% 46

Other funds holding XBI

KB Financial Partners's XBI Position: Q2 2023 in Review

KB Financial Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2023, closing a stake of 9,691 shares — an estimated $739K sold.

KB Financial Partners first reported a position in XBI in Q2 2022 and held it in 4 quarters. The position peaked at $796K in Q4 2022. 713 funds tracked by Wall St. Rank hold XBI as of Q2 2023.

  • KB Financial Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2023 after selling out during the quarter.
  • KB Financial Partners sold 9,691 State Street SPDR S&P Biotech ETF shares in Q2 2023, an estimated $739K.
  • KB Financial Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and held it in 4 quarters.
  • KB Financial Partners's State Street SPDR S&P Biotech ETF position peaked at $796K in Q4 2022.
  • 713 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2023.

Based on KB Financial Partners's 13F filing for Q2 2023, filed 15 Aug 2023.